MetriTrack is excited to announce that it has raised $1.5M in seed funding. This funding will be used to complete the development of the MetriTrack BVN-G2000 first prototype system. In addition, this funding will support collection of clinical data to validate the exceptional precision mapping capabilities for the breast and axilla that the technology is designed for.
For instance, the BVN-G2000 is designed to provide precise tumor localization within <1 cm when used in conjunction with handheld ultrasound, which is clinically significant for breast cancer care.
This innovation could in particular save lives for >50% of women globally with dense breast tissue.